HC Wainwright & Co. maintains Buy rating on NeuroSense Therapeutics, $52 price target

HC Wainwright & Co. maintained their Buy rating on NeuroSense Therapeutics's stock with a price target of $52.00.The price target implies an upside of 648.2% from the Sep 25 close of $6.95.Key takeaways from the analyst notePositive Clinical Trial Prospects: NeuroSense Therapeutics is advancing its…